|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03347 TIGERMED
Nominal 
32.350 -1.650 (-4.853%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 3,358,244 | -9.502% | 7,384,039 | 7,085,471 | 5,213,538 | 3,192,279 |
| Cost of Sales | -- | -- | (4,563,378) | (4,300,027) | (2,965,420) | (1,688,946) |
| Gross Profit | -- | -- | 2,820,661 | 2,785,444 | 2,248,118 | 1,503,333 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (134,487) | -- | (68,098) | (24,575) | (24,426) | 10,075 | |
| Profit / (Loss) on Disposal | 1,490 | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | (3,567) | |
| Share of Results of Asso. & JCEs | 44,095 | -30.803% | 105,183 | 39,763 | 14,348 | (3,508) | |
| Profit / (Loss) before Taxation | 690,093 | -56.846% | 2,490,191 | 2,594,912 | 3,689,502 | 2,220,262 | |
| Taxation | (132,514) | -30.641% | (338,606) | (313,652) | (292,864) | (189,707) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (64,730) | 227.696% | (125,078) | (265,174) | (517,539) | (279,227) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 492,849 | -64.501% | 2,026,507 | 2,016,086 | 2,879,099 | 1,751,328 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (16,109) | -77.004% | (110,927) | (145,249) | (234,139) | (63,317) |
| Depreciation & Amortisation | 180,372 | 11.273% | 339,024 | 284,844 | 196,762 | 150,256 |
| Directors' Emoluments | -- | -- | 8,929 | 7,871 | 3,487 | 3,395 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 57.000 | -64.596% | 234.000 | 233.000 | 332.000 | 220.000 |
| DPS (cts) | 0.000 | -- | 56.800 | 55.000 | 50.000 | 30.000 |
| Dividend Payout Ratio (%) | -- | -- | 24.274% | 23.605% | 15.060% | 13.636% |
| Cash flow per share ($) | -- | -- | 1.077 | 1.311 | 1.343 | 1.125 |
| NBV per share ($) | 24.007 | -- | 24.150 | 22.499 | 20.844 | 18.514 |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 492,849 |
| %Change | -64.501% |
| EPS / (LPS) | RMB 0.570 |
| NBV Per Share (¥) | RMB 24.007 |